SUBSCRIBE TO THE ARx NEWSLETTER

ARx develops and manufactures transdermal and transmucosal drug delivery programs, including the first oral thin film for systemic drug delivery. This newsletter covers the biopharmaceutical, regulatory, and process decisions that those programs require.

If you’re:

• Selecting a delivery route based on optimizing permeability, bypassing first-pass metabolism, or reducing PK variability
• Reformulating a candidate after a bioavailability, stability, or manufacturability failure
• Managing analytical and process technology transfer against a time-to-market deadline

Subscribe for formulation and regulatory insight →